pazopanib and Hyperglycemia

pazopanib has been researched along with Hyperglycemia* in 1 studies

Other Studies

1 other study(ies) available for pazopanib and Hyperglycemia

ArticleYear
Severe hyperglycaemia following pazopanib treatment: The role of drug-drug-gene interactions in a patient with metastatic renal cell carcinoma-A case report.
    Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:4

    Pazopanib is a tyrosine kinase inhibitor with hyperglycaemia as a known adverse event, but case reports of severe hyperglycaemia are exceptional. We report a case of severe hyperglycaemia following pazopanib administration in a patient with metastatic renal cell carcinoma.. Severe hyperglycaemia developed in a patient one month following initiation of pazopanib therapy. As drug-drug-gene interactions may lead to hyperglycaemia, pharmacogenetic assessment was requested. The obtained findings indicated intermediate function of both OATP1B1 and P-glycoprotein transporters, which may cause prolonged pazopanib bioavailability and increased toxicity. Pazopanib was discontinued and, following patient recovery, was reintroduced at a lower dose.. The pharmacogenetic profiling of the patient on polypharmacy enabled better management of pazopanib therapy.

    Topics: Aged; Carcinoma, Renal Cell; Drug Interactions; Humans; Hyperglycemia; Indazoles; Kidney Neoplasms; Male; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides

2020